Press Releases for SGP

Press Releases
Merck and Schering-Plough to Complete Merger Today
Ligand to Acquire Metabasis for Cash and Contingent Value Rights
RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on OLN, LXK, SGP, MMM, LYG and STSI
Abbott to buy Solvay division for $6.6B
Fitch: Credit Quality Stable for Global Pharma Sector With Increase of New Drug Approvals in 2Q'09
Schering-Plough Announces Two European Filings
Saphris OK'd for schizophrenia
SCHERING-PLOUGH ANNOUNCES FDA APPROVAL OF SAPHRIS(R) (asenapine): for acute treatment of schizophrenia in adults and manic or mixed episodes of bipolar I disorder with or without psychotic features in adults
Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults
Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)
BenchmarkJournal.Com Free Analyst Review for PGH, JEC, PL, SGP, UPS and WCC
Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours
PTC Therapeutics Announces Achievement of Major Milestone in Schering-Plough Hepatitis C Collaboration
Schering-Plough Shareholders Approve Merger With Merck
ParagonReport.Com Complimentary Market Update on Alumina Ltd. (NYSE: AWC), CSB Corporation (NYSE: CBS), Merck &Amp; Co. Inc. (NYSE: MRK) and NVIDIA Corporation (NASDAQ: NVDA)
Merck Shareholders Approve Merger With Schering-Plough
Schering-Plough to Webcast Special Meeting of Shareholders
Seeger Weiss Announces Global Resolution of Zetia and Vytorin Prescription Purchase Claims -- MRK, SGP
Hagens Berman Sobol Shapiro: Vytorin and Zetia Makers Settle Class-Action Suit With Proposed $41.5 Million
Merck and Schering-Plough Resolve Previously Disclosed Civil Class Action Lawsuits Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe)
/C O R R E C T I O N -- Schering-Plough Corporation/
FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
Sanofi-aventis to Acquire Merck's Interest in Merial
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger With Merck
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
Breaking Investors Alert for Wednesday: ARWD! July 22, 2009
Schering-Plough Reports Financial Results for 2009 Second Quarter ; Diversification Strategy and Strong Execution Continue to Drive Solid Performance;; Robust Pipeline Continues To Advance and Build Long-Term Value
Baucus reels in big healthcare donations
Schering-Plough Reports Financial Results for 2009 Second Quarter
Merck and Schering-Plough Resolve Previously Disclosed Investigation Under State Consumer Protection Statutes Related to VYTORIN® (ezetimibe/simvastatin) and ZETIA® (ezetimibe)
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients
ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus
Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
SAFE-BioPharma Changes Fees to Help Clinical Investigators, CROs, Others
Merck and Schering-Plough Receive Request for Additional Information from FTC Regarding Proposed Merger
The New York Yankees' Mark Teixeira, National Foundation For Cancer Research, and the Makers of COPPERTONE SPORT(R) Launch 'Help Strike Out Sun Damage' Program
June 23 DIA Sessions Chaired By SAFE-BioPharma Association
New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives
Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
Schering-Plough and Merck Provide Update on Distribution Agreement
Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Photos: Schering-Plough Introduces DR. SCHOLL'S(R) FOR HER High Heel Insoles to Help Prevent Foot Aches and Pains
Redpoint Bio Reports First Quarter 2009 Results
Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair
Schering-Plough Schedules Webcast For Annual Meeting of Shareholders
Schering-Plough Starts Patient Enrollment in Phase 3 Trial for Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery
Schering-Plough Reports Financial Results for 2009 First Quarter - Apr 21 2009 10:56AM
Schering-Plough Reports Financial Results for 2009 First Quarter - Apr 21 2009 6:55AM
Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay
Zacks Analyst Blog Highlights: Schering-Plough, Merck &Amp; Co., Johnson &Amp; Johnson, Masimo Corp. And Public Service Enterprise Group.
Schering-Plough Announces Results of the Early ACS Trial
EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year
Research and Markets: Medicated Skin Care Products - Global Strategic Business Report
Wall Street News Alert Reports Wednesday's Stocks to Watch: OCOL! March 18, 2009
Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM)
Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Zacks Analyst Blog Highlights: Ciena Corp, Kimberly-Clark, Cytori Therapeutics Inc, Merck & Co and Schering-Plough Corp.
Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
Merck and Schering-Plough to Merge
Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Zacks Analyst Blog Highlights: Schering-Plough, Pfizer, Bristol-Myers, Citigroup and Credit Suisse Group
Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards
Zacks Analyst Blog Highlights: Intel, Vertex Pharmaceuticals, Schering-Plough, Vocus and Sohu.Com, Inc.
Schering-Plough Reports Financial Results for 2008 Fourth Quarter, Full Year
Brooke Shields and the Makers of COPPERTONE(R) Join Together to Launch COPPERTONE(R) NutraShield(TM) - New Sunscreen Contains Antioxidants That Promote Natural Skin Repair
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Schering-Plough Selects Benefit Advocates for Health Advocacy
New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings
Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
Schering-Plough Provides Update on Dividend Payment Date for Mandatory Convertible Preferred Stock
Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
Standard & Poor's Announces Changes to U.S. Indices - 11-12-08
Global Mapping Tool Demonstrates Medical Donation Impact
Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock - Dec 10 2008 1:38PM
BridgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on COP, BSX, SGP and XTO
CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
Seven Summits Research Releases Alerts on RIMM, JPM, SGP, BG, and MR
Schering-Plough to Webcast R&D Update Meeting
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case